Another Choice for Prevention of COPD Exacerbations.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease.Journal of thoracic disease · 2020
   Review
2. MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease.Respiratory research · 2018
   Article
3. When is dual bronchodilation indicated in COPD?International journal of chronic obstructive pulmonary disease · 2017
   Review
4. Dual bronchodilation and exacerbations of COPD.Journal of thoracic disease · 2016
   Article

Corrections and comments

• Comment on
  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as